CG Oncology

Today we are proud to announce the initiation of our Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP, and enrollment is ongoing. 📄 Read the full release here: https://bit.ly/3Rv5a7C Healthcare providers and bladder cancer patients who are interested to learn more about CG Oncology’s EAP including eligibility criteria may visit www.clinicaltrials.gov, NCT06443944, or contact EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

Despite progress in #bladdercancer treatment, several gaps persist in treating patients with High-Risk BCG-unresponsive #NMIBC. Hear from Sima Porten, MD, MPH, Associate Professor in Residence at UCSF, as she analyzes the current treatment landscape. #Urology #BladderCancer

At CG Oncology we have a lot to be grateful for on Thanksgiving and all year round. We have a talented team that pursues our mission with passion every day. However, our work would not be possible without the patients who participate in our clinical trials, as well as the investigators and their staff who conduct them. We truly appreciate their contributions to research!

Did you know? #BladderCancer is the 6th most common cancer in the United States, with an estimated 83,000 new cases in 2024. Our investigational drug, cretostimogene grenadenorepvec, is designed to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (#NMIBC) – which represents 75% of all new bladder cancer cases. Learn more: https://bit.ly/48IZnmi #Urology

CG Oncology is excited to announce & welcome our newest additions to the team: Wofe' Cornwall - Sr. Director, National & Strategic Accounts - Head of Payers Andrea Strong, - Medical Science Liaison David Dai - Sr. Director, Pricing & Strategy Mike Swift, CPA, MBA - Sr. Manager, Financial Planning & Analysis Kristen Scholz - Vice President, Medical Affairs Ian Oldham - Director, Regulatory Operations

Hear from Ashish Kamat, MD, MBBS, Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at The University of Texas MD Anderson Cancer Center as he discusses the unmet need in the U.S. for a bladder-sparing therapy for patients who are unresponsive or cannot access BCG. #BladderCancer #Urology

CG Oncology is thrilled to once again present at the Annual Meeting of the Society of Urologic Oncology, Inc #SUO2024 in Dallas, Texas, from December 4-6. While there, our team will share insights on our lead candidate, cretostimogene grenadenorepvec, an innovative, intravesically delivered oncolytic immunotherapy for the treatment of BCG-unresponsive #NMIBC. Mark your calendars for Thursday, Dec. 5 at 11:45 when we will share data from our Phase 3 BOND-003 study. View the agenda here: https://bit.ly/4fCfm7Y #SUO #SUO24 #SUO #BladderCancer #Urology

Today, CG Oncology announced Nature Medicine's publication of phase 1b study results evaluating cretostimogene grenadenorepvec in combination with nivolumab in Muscle-Invasive Bladder Cancer, as well as the simultaneous presentation at the Society for Immunotherapy of Cancer 2024. The encouraging data adds to the body of evidence supporting the potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer. Check out the release here: https://lnkd.in/eFgRnRZH

The Bladder Cancer Advocacy Network recently held a Summit in Philadelphia where members of the Bladder Cancer community including patients, care givers, health care providers and members of industry came together. Over the course of the two day meeting we learned about BCAN's innovations in bladder cancer support, heard expert advice on navigating survivorship and nurturing urinary and bladder health post-treatment, and learned about advancements in bladder cancer research. We also had the opportunity to speak with many patients about their journeys with bladder cancer, which underscored the importance of new treatment options. Thank you to BCAN for convening such a meaningful forum and welcoming us to participate. -with Elaine Harris, Kristen M., Andrea Maddox-Smith and Sarah Connors

CG Oncology is excited to announce & welcome our newest additions to the team: Chau Cheng - Vice President, Investor Relations Daytriona Clemons, PharmD - Clinical Trials Scientist Abhishek Sharma - Sr. Director, Health Economics & Outcomes Research Anvita Valluru - Sr. Associate, CMC Strategy & Submissions Wesley Williams, PhD - Sr. Scientist, Materials, Science & Technology Marian Escobar - Accounts Payable Specialist Aman D. - Director, Talent Acquisition & Total Rewards Gay Gauvin - Associate Vice President, Technical Operations Karen To - Associate Director, Clinical Supply Chain